Olanzapine decreased osteocyte maturation and Wnt/β-catenin signaling during loading of the alveolar bone in rats.


Journal

Biomolecules & biomedicine
ISSN: 2831-090X
Titre abrégé: Biomol Biomed
Pays: Bosnia and Herzegovina
ID NLM: 9918522188506676

Informations de publication

Date de publication:
01 Feb 2023
Historique:
received: 16 05 2022
accepted: 09 07 2022
pubmed: 27 7 2022
medline: 3 2 2023
entrez: 26 7 2022
Statut: epublish

Résumé

Several studies indicate the influence of olanzapine on bone metabolism; however, the results are contradictory. We evaluated the effects of olanzapine on the Wnt/β-catenin signaling pathway, physiological alveolar bone turnover, and alveolar bone modeling due to an applied orthodontic force. Adult male rats (n=48) were treated with either olanzapine or a vehicle for 21 days; then 8 rats from each group were sacrificed and the rest were divided into 4 groups: control, appliance-only, olanzapine-only, and olanzapine-appliance. The rats in the appliance groups were mounted with a superelastic closed coil spring that maintained constant orthodontic force between molars and incisors. We studied the effects of olanzapine on physiological alveolar bone turnover on day 21 of the experiment, and on alveolar bone modeling due to orthodontic force on day 56. We determined tooth movement, alveolar bone volume, activity of bone-specific cells, serum alkaline phosphatase (ALP) activity, and gene expression levels of Wnt/β-catenin signaling target genes. During forced bone modeling, olanzapine increased osteoblast volume (P<0.0001) and ALP activity (P=0.0011) and decreased osteoclast volume (P<0.0001) and gene expression of the Wnt/β-catenin signaling target genes Fosl1, Axin2, and Dkk1(P=0.001, P=0.0076, and P=0.036, respectively), and the osteocyte markers Sost and Dmp1 (P=0.0432 and P=0.0021, respectively). Similar results were obtained during physiological alveolar bone turnover on day 21, when olanzapine downregulated the gene expression of osteocyte markers and Wnt/β-catenin signaling target genes. We concluded that olanzapine attenuated osteocyte maturation during forced bone modeling and physiological alveolar bone turnover, potentially through downregulation of the Wnt/β-catenin signaling pathway.

Identifiants

pubmed: 35880348
doi: 10.17305/bjbms.2022.7523
pmc: PMC9901902
doi:

Substances chimiques

beta Catenin 0
Olanzapine N7U69T4SZR

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114-125

Références

Clin Chem Lab Med. 2011 Sep;49(9):1439-46
pubmed: 21702699
Int J Endocrinol. 2019 Mar 21;2019:1312804
pubmed: 31019532
Behav Pharmacol. 2007 Sep;18(5-6):391-418
pubmed: 17762509
Am J Orthod Dentofacial Orthop. 2020 Jul;158(1):16-27
pubmed: 32381434
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2567-72
pubmed: 22308416
Mol Cell Biol. 2002 Feb;22(4):1184-93
pubmed: 11809809
Nat Med. 2011 Sep 11;17(10):1235-41
pubmed: 21909103
Nat Genet. 2006 Nov;38(11):1310-5
pubmed: 17033621
BMC Pharmacol Toxicol. 2019 Feb 12;20(1):10
pubmed: 30755277
Comp Med. 2008 Oct;58(5):424-30
pubmed: 19004367
Curr Psychiatry Rep. 2021 Nov 29;23(12):87
pubmed: 34843030
Am J Orthod Dentofacial Orthop. 2006 Apr;129(4):555-8
pubmed: 16627184
J Mol Histol. 2016 Oct;47(5):455-66
pubmed: 27456852
ScientificWorldJournal. 2015;2015:876509
pubmed: 26421314
Am J Orthod Dentofacial Orthop. 2004 May;125(5):615-23
pubmed: 15127031
Ann N Y Acad Sci. 2006 Apr;1068:165-72
pubmed: 16831915
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):1-4
pubmed: 19922755
J Dent Res. 2018 Nov;97(12):1374-1382
pubmed: 29863952
Front Pharmacol. 2018 Apr 16;9:379
pubmed: 29713286
PLoS One. 2016 Feb 23;11(2):e0150102
pubmed: 26907598
Am J Orthod Dentofacial Orthop. 2006 Apr;129(4):469.e1-32
pubmed: 16627171
Br J Psychiatry. 2004 Jun;184:503-8
pubmed: 15172944
Am J Psychiatry. 2010 Apr;167(4):388-96
pubmed: 19917593
J Clin Psychiatry. 2003 Jul;64(7):761-6
pubmed: 12934975
J Periodontol. 2015 Feb;86(2):319-26
pubmed: 25345341
JBMR Plus. 2019 Jun 13;4(7):e10080
pubmed: 32666016
Bone. 2008 Apr;42(4):606-15
pubmed: 18280232
Acta Odontol Scand. 2016;74(3):217-23
pubmed: 26414930
EMBO J. 2005 Jan 12;24(1):73-84
pubmed: 15592430
Schizophr Res. 2007 Jul;93(1-3):136-43
pubmed: 17467954
FASEB J. 2005 Nov;19(13):1842-4
pubmed: 16123173
Biofactors. 2010 Jan-Feb;36(1):25-32
pubmed: 20087883
Dev Cell. 2005 May;8(5):751-64
pubmed: 15866165
FASEB J. 2010 Oct;24(10):3625-32
pubmed: 20505115
Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):E478-86
pubmed: 25605937
Psychopharmacology (Berl). 1999 Jan;141(3):267-78
pubmed: 10027508
Medicine (Baltimore). 2015 Nov;94(47):e1967
pubmed: 26632691
Bone. 2008 Oct;43(4):740-7
pubmed: 18656564
Clin Genet. 2013 Jun;83(6):511-7
pubmed: 23379509
Nat Rev Endocrinol. 2016 Oct;12(10):593-605
pubmed: 27230951
Eur J Pharmacol. 2001 Nov 2;430(2-3):341-9
pubmed: 11711053
J Dent Res. 2018 Aug;97(9):1031-1038
pubmed: 29617179
Ther Adv Psychopharmacol. 2013 Oct;3(5):278-93
pubmed: 24167704
Front Endocrinol (Lausanne). 2015 Jan 20;5:246
pubmed: 25653639
Psychopharmacology (Berl). 2005 Aug;181(1):80-9
pubmed: 15778884
Oncogene. 2005 Feb 3;24(6):1098-103
pubmed: 15592505
Curr Osteoporos Rep. 2012 Jun;10(2):109-17
pubmed: 22427140
J Bone Miner Res. 1997 Jun;12(6):869-79
pubmed: 9169344
Mol Cell Biol. 2010 Jun;30(12):3071-85
pubmed: 20404086
J Biol Chem. 2006 Oct 20;281(42):31720-8
pubmed: 16908522
J Bone Miner Res. 2014 Mar;29(3):705-15
pubmed: 23929793
Eur J Orthod. 2004 Oct;26(5):483-90
pubmed: 15536836
Biol Psychiatry. 2005 Mar 1;57(5):533-42
pubmed: 15737669
Lancet. 2019 Sep 14;394(10202):939-951
pubmed: 31303314
Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1603-8
pubmed: 9990071
Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:97-108
pubmed: 12650684
J Pharmacol Exp Ther. 2003 May;305(2):625-31
pubmed: 12606608
Clin Psychopharmacol Neurosci. 2016 Aug 31;14(3):238-49
pubmed: 27489377
Am J Orthod Dentofacial Orthop. 2015 Dec;148(6):1017-25
pubmed: 26672708
Schizophr Res. 2011 Mar;126(1-3):291-7
pubmed: 21185156
Mol Cell Biol. 2002 Feb;22(4):1172-83
pubmed: 11809808
J Bone Miner Res. 2003 May;18(5):807-17
pubmed: 12733719
Am J Orthod Dentofacial Orthop. 2011 Apr;139(4):e323-9
pubmed: 21457838

Auteurs

Saranda Disha-Ibrahimi (S)

Department of Orthodontics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; Department of Periodontology and Oral Medicine, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo.

Borut Furlani (B)

Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Gorazd Drevenšek (G)

Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Samo Hudoklin (S)

Institute of Cell Biology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Janja Marc (J)

Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.

Irena Prodan Žitnik (I)

Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia.

Jakob Sajovic (J)

Institute of Pharmacology and Experimental Toxicology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; Department of Orthodontics, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Martina Drevenšek (M)

Department of Orthodontics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; Department of Orthodontics, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH